Compliance · State rules

Office-use compounding in Florida

Not authorised for human office use; veterinary only

USPeptideRx EditorialLast reviewed: August 28, 2026

Florida does not authorise human office use. Since April 9, 2025 the only affirmative office-use grant in Fla. Admin. Code R. 64B16-27.700 has been veterinary, and human compounding practices — the rule names office stock and office use expressly — are made a pure pass-through to 21 U.S.C. §§ 353a and 353b, which condition the federal exemptions on a patient-specific prescription. Florida is not silent on this: it addresses human office use and declines to authorise it on its own.

The governing rule

Florida’s office-use position is set by Fla. Admin. Code R. 64B16-27.700(3)–(4). The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

Fla. Admin. Code R. 64B16-27.700(3) — the only affirmative grant, and it is veterinary

(3) Veterinary office use compounding, "Office use" means the provision and administration of a compounded drug to a patient by a veterinarian, veterinarian assistant, or veterinarian technician in the practitioner’s office and the administration of a compounded medication by a veterinarian to a patient outside the office for veterinary use only. A pharmacist may dispense and deliver a quantity of a compounded drug to an aforementioned practitioner for veterinary office use by the practitioner in accordance with this section provided: ...

Fla. Admin. Code R. 64B16-27.700(4) — human use, a federal pass-through

(4) Human Use Compounded Drug Products: Compounding of drug products and compounding practices such as patient-specific, anticipatory, office stock or office use, and other legally permissible forms, must strictly adhere to relevant federal regulations, including but not limited to 21 USC 353a and 21 USC 353b.

Fla. Admin. Code R. 64B16-27.797(2) — the Board states the federal predicate plainly

Section 503A of the FD&C Act, codified at 21 U.S.C. 353a, requires compliance with minimum practice and quality standards for compounding sterile drug products pursuant to a valid prescription for an identified patient.

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The misattributed statuteHigh confidence: Fla. Stat. § 465.0265 is titled "Centralized prescription filling" and governs one pharmacy filling prescriptions for another. It contains no office-use language. It appears in the rule’s "Law Implemented" line, which is almost certainly the origin of the misattribution. There is no office-use statute anywhere in Chapter 465.
Rule numbers commonly cited wronglyHigh confidence: "64B16-27.7001" and "64B16-27.7971" do not exist. The operative rules are 64B16-27.700 (compounding) and 64B16-27.797 (sterile compounding).
Sterile and non-sterile alikeHigh confidence: Subsection (4) says "drug products" with no sterility qualifier, so there is no sterile carve-out. The Board said so expressly when it wrote the provision in 2017: the purpose was to make clear that office use compounding of products intended for human use, sterile and nonsterile, requires registration as an outsourcing facility.
The legend was repealedHigh confidence: The "For Institutional or Office Use Only – Not for Resale" legend formerly sat at 64B16-27.700(3)(f)6 and was repealed effective April 9, 2025. The provision now reads simply "The statement ‘Compounded Drug.’" and attaches only to veterinary products.Any copy claiming Florida requires that legend is citing a repealed provision. Texas has a near-identical legend that is current — do not let the two be confused.
The deleted administer-only clauseHigh confidence: The explicit administer-only clause at former (3)(d)1 was deleted effective March 10, 2026; the Board’s stated purpose was to remove unnecessary language from the text. This is not a liberalisation for human use — the clause already sat inside subsection (3), which had been confined to veterinary use in April 2025.The deletion is verified. The likely cause — a conflict with § 465.0276(5), which permits a veterinarian to dispense to an owner — is inference and is low confidence.
The 3% figure is a wholesale exemption, not a permissionHigh confidence: Fla. Stat. § 499.003(48)(m) excludes from "wholesale distribution" the distribution of minimal quantities of prescription drugs by a licensed retail pharmacy to a licensed practitioner for office use "in compliance with chapter 465 and rules adopted thereunder", and provides that until such rules are adopted minimal quantities may not exceed 3 percent of the pharmacy’s total annual purchases of prescription drugs.It answers whether a pharmacy needs a wholesaler permit, not whether it may compound without a prescription, and it is expressly conditioned on compliance with Chapter 465 — which routes straight back to 64B16-27.700(4) and federal law. The contemplated minimal- quantity rules were never adopted, and the rule that would have carried them affirmatively excludes regular and systematic sales to practitioners for routine office procedures.
Two structural bars for human productsHigh confidence: Even setting subsection (4) aside, 64B16-28.108(2) requires every dispensed human container to bear the name of the patient and the name of the prescriber, and 64B16-28.140(4)(i) requires the compounding batch record to include the name of the patient who received the particular compounded product. Florida provides no office-stock label format for human drugs.
A federal violation is an independent Florida disciplinary groundHigh confidence: Fla. Stat. § 465.016(1)(e) makes violating chapter 499 or 21 U.S.C. ss. 301-392 — the Federal Food, Drug, and Cosmetic Act — a ground for discipline in its own right. Federal exposure here is also state exposure.
RecordkeepingHigh confidence: Four years (64B16-28.140(1)(d), (f)2 and (g)3). The explicit "minimum of four (4) years" phrase was deleted from the office-use records provision on April 9, 2025 and replaced with a cross-reference plus "readily retrievable within 72 hours"; the four-year period still applies through the cross-reference.High confidence on the four-year period; medium on the cross-reference mechanism.
ReportingHigh confidence: None routine. Two incident-triggered duties only: loss of data-system information reported within 10 days (64B16-28.140(1)(h)), and a corrective action plan for a sterile deficiency within 30 days (64B16-27.797(5)).
Out-of-state pharmaciesHigh confidence: A permit adds requirements; it does not add permission. Fla. Stat. § 465.0156 governs nonresident pharmacy registration and § 465.0158 requires a Nonresident Sterile Compounding Permit to "ship, mail, deliver, or dispense a compounded sterile product into Florida" — verbs that reach non-patient-specific shipments. Section 465.0158(4) bars shipping product that fails Florida’s sterile standards, which incorporate 64B16-27.797, which incorporates the identified-patient predicate. The permit imports the prescription requirement rather than escaping it.
Last changeHigh confidence: Three amendments in 17 months. The rule’s history reads: new 10-1-92; amended 11-2-03, 10-7-08, 3-21-13, 6-22-14, 1-28-18, 4-9-25, 3-10-26, 8-3-26. April 9, 2025 was the structural change — it inserted "Veterinary" into subsection (3), added "for veterinary use only", narrowed the recipients to veterinarians and their assistants and technicians, deleted the extension to a health care facility or treatment setting, deleted the office-use label legend, deleted the former express outsourcing-facility mandate and added subsection (4). Both 2026 amendments touched only the veterinary subsection; subsection (4) has been stable since April 9, 2025.No 2025 or 2026 session law amended the relevant statutes. That finding rests on statute history notes rather than a bill-by-bill sweep, so it is medium-high rather than high.

Florida at a glance

Florida office-use compounding summary, reviewed 2026-08-28
Human office use	Not authorised — a pure federal pass-through
Sterile preparations	Both barred for human use; no sterile carve-out
Quantity cap	The 3% figure is a wholesale exemption, not a permission
Mandatory label legend	Human legend repealed Apr 2025; veterinary "Compounded Drug."
Board reporting	Incident-driven only — 10-day and 30-day duties
Last change	August 3, 2026
Governing rule	Fla. Admin. Code R. 64B16-27.700(3)–(4)

Receiving 503B office stock in Florida

Florida licenses the facility through the Board of Pharmacy rather than the department most people check, and it is one of the few states that puts a permit on the receiving practice — keyed to who signs the purchase order. Florida does not, however, mandate the 503B route: rule text requiring registration as an outsourcing facility for human office-use compounding was proposed in 2024 and struck the same year after a Joint Administrative Procedures Committee objection.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Florida asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: A nonresident sterile compounding permit from the Board of Pharmacy. Fla. Stat. § 465.0158(1): to "ship, mail, deliver, or dispense, in any manner, a compounded sterile product into this state", a nonresident pharmacy "or an outsourcing facility, must hold a nonresident sterile compounding permit." Not DBPR and not Chapter 499 — the word "outsourcing" appears zero times across §§ 499.003, 499.01 and 499.012.Two open ends worth naming. Whether a 503B also needs a Chapter 499 permit is genuinely unresolved. And § 465.0158 by its terms covers only a compounded STERILE product — no Florida permit was found covering a 503B shipping non-sterile office stock into the state.
Does your practice need a permit?High confidence: Yes if the business entity buys; no if the practitioner does. § 499.01(1)(r) requires "a health care clinic establishment permit … for the purchase of a prescription drug by a place of business … owned and operated by a business entity that has been issued a federal employer tax identification number", and § 499.01(2)(r)6 carves out only "the purchase of a prescription drug by a licensed practitioner under his or her license." Bought in the doctor’s own name and licence, no permit. Bought by the LLC, permit.The permit requires designating a qualifying practitioner responsible for purchase, recordkeeping, storage and handling, whose name and licence number appear on all distribution documents. Do not confuse it with the AHCA "health care clinic" licence under Chapter 400 Part X, which is about billing and reimbursement — confusingly similar name, entirely different regime.
Administer vs dispenseHigh confidence: Florida settles the threshold by statute. § 465.003(13): "The administration shall not be considered dispensing." A practice that only administers does not inherit the pharmacy labelling and record rules; § 465.0276(2)(b) makes a registered dispensing practitioner "comply with and be subject to all laws and rules applicable to pharmacists and pharmacies", so one that dispenses does.Both feared traps miss a practice that only administers: 64B16-28.108 is keyed to drugs "dispensed to a patient", and 64B16-28.140 sits in a rule binding pharmacy permit holders. Stock arriving under federal § 353b(a)(10) labelling with no patient name is correct, not a violation.
Scheduled (controlled) stockHigh confidence: The biggest practical trap in Florida. § 465.0276(1)(b) provides that a practitioner registered to dispense "may not dispense a controlled substance listed in Schedule II or Schedule III", subject only to narrow exceptions. Administering compounded testosterone in the office and sending a patient home with a vial are different acts with different answers. Florida has no separate state controlled-substance registration — § 893.02(23) builds the DEA number into the definition of practitioner.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Florida compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

Florida’s rule moved three times in 17 months, most recently three weeks before this review. Treat any Florida statement here as short-shelf-life, and re-check the rules docket before relying on it.
Section 465.019 (institutional pharmacies) and § 465.0196 are unread. If your setting is a hospital or an ambulatory surgical centre rather than an office or a med spa, the institutional floor-stock architecture is a real gap in this page.
The full context of § 499.01(2)(g), the 30 percent wholesale threshold, is not established here — we read its operative sentence and nothing around it.
We searched for no Board declaratory statement, newsletter, FAQ or administrative-hearing order on human office use.
Beyond the primary sources cited here, we have not surveyed board newsletters, declaratory statements, enforcement actions, disciplinary orders or coverage of pending bills. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.